Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target (Q38202910)

30 August 2017

Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target (English)

1 reference

30 August 2017

0 references

0 references

0 references

Sanjay W Pimplikar

1

1 reference

30 August 2017

8 April 2014

1 reference

Journal of Clinical Immunology

30 August 2017

1 reference

30 August 2017

34 Suppl 1

1 reference

30 August 2017

S64-9

1 reference

https://scigraph.springernature.com/pub.10.1007/s10875-014-0032-5

30 August 2017

0 references

cites work

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Alzheimer's disease: genetic studies and transgenic models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Brain β-amyloid load approaches a plateau

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Deciphering the molecular basis of memory failure in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Tau in Alzheimer disease and related tauopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Presenilin mutations in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

The value of incomplete mouse models of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Mouse models of Alzheimer's disease: The long and filamentous road

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Alzheimer's disease: the amyloid cascade hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

The molecular pathology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Trans-synaptic spread of tau pathology in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Molecular drivers and cortical spread of lateral entorhinal cortex dysfunction in preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Tau reduction prevents Abeta-induced defects in axonal transport.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Tau protein is required for amyloid {beta}-induced impairment of hippocampal long-term potentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Epothilone D improves microtubule density, axonal integrity, and cognition in a transgenic mouse model of tauopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Reassessing the amyloid cascade hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Amyloid-independent mechanisms in Alzheimer's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Toward a multifactorial model of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Genes and pathways underlying regional and cell type changes in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Protective effects of NSAIDs on the development of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Risk of Alzheimer's disease and duration of NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Inflammation and Alzheimer's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Increased interleukin-1beta converting enzyme expression and activity in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Systemic inflammation and disease progression in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Systemic infections and inflammation affect chronic neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Blood protein signature for the early diagnosis of Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

The role of cytokines in the regulation of neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Evidence for a cytokine model of cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Neuroinflammation and memory: the role of prostaglandins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Neuroinflammation and synaptic loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Inflammation in neurodegenerative disease--a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

ADAPT: the wrong way to stop a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Extended results of the Alzheimer's disease anti-inflammatory prevention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Intravenous immunoglobulins: a treatment for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Mechanisms of action of intravenous immunoglobulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers Aβ in APP/PS1 mice along a different time course than anti-Aβ antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

The A4 study: stopping AD before symptoms begin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Mediterranean diet, cognitive function, and dementia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Exercise builds brain health: key roles of growth factor cascades and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-014-0032-5

Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis

21 January 2018

1 reference

12 December 2020

Effectiveness of exercise on cognitive impairment and Alzheimer's disease

1 reference

12 December 2020

Why are drug trials in Alzheimer's disease failing?

1 reference

12 December 2020

Inflammation in Alzheimer disease: driving force, bystander or beneficial response?

1 reference

12 December 2020

Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease.

1 reference

12 December 2020

10.1007/S10875-014-0032-5

Identifiers

DOI

1 reference

PubMed ID

24711006

Dimensions Publication ID

30 August 2017

0 references

1 reference

PubMed ID

24711006